FDA Nudge Sends Pharma Stock to Fresh Record Highs

LLY options are looking cheap at the moment, too

Managing Editor
Jun 11, 2024 at 10:00 AM
facebook X logo linkedin

Shares of Eli Lilly And Co (NYSE:LLY) are enjoying a 2.3% surge this morning, last seen trading near $885.10 on the back of news that the Food and Drug Administration (FDA) panel unanimously approved the pharmaceutical company's Alzheimer's drug, donanemab. The FDA cited effectiveness and a beneficial risk/reward outcome.

In response, several analysts have donned praise, Jefferies hiking its price target to $994 from $957, saying the FDA backing is a good look for future label/screening equipment. Heading into today analysts are mostly bullish, with 19 of the 22 in coverage sporting a "buy" or "strong buy" recommendation. There is still room for more price-target hikes, with the stock's 12-month average price target coming in at $863.75, 2.5% below Monday's close.

LLY has been an exceptional outperformer on the charts, up 94% over the last 12 months and 50% since the start of 2024. The stock is now eyeing its 10th win in 11 days, and out of the gate today hit a new record high of $882.14. Longer-term, a trendline of support has been found at the ascending 80-day moving average.

Options are looking affordable too. This is per the stock's Schaeffer's Volatility Index (SVI) of 26%, which ranks in the 29th percentile of its annual range, meaning options traders are pricing in low volatility expectations at the moment.


Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.

Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!




Rainmaker Ads CGI